ArticleNaunyn-Schmiedeberg's archives of pharmacology2026
Real-world safety profile of eravacycline compared with tigecycline, minocycline, and meropenem: a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS).
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eravacycline is a novel fluorocycline antibiotic approved for complicated intra-abdominal infections and hospital-acquired/ventilator-associated bacterial pneumonia. Its real-world adverse event profile and patterns of off-label use remain incompletely characterized. We conducted a comparative pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) covering 2014Q1-2025Q4. Eravacycline suspect cases (2019Q1-2025Q4) were compared with tigecycline, minocycline, and meropenem suspect cases. Serious outcome rates were compared using chi-square or Fisher's exact test. Disproportionality analysis used the Reporting Odds Ratio (ROR) with the pooled comparator reports as background reference. Two distinct definitions of off-label use were employed: reporter-coded MedDRA PT "off label use," and indication-based classification. All analyses are exploratory. A total of 158 eravacycline suspect cases were identified. Serious outcomes were observed in 67.1% of eravacycline cases, significantly lower than tigecycline (93.9%), minocycline (86.0%), and meropenem (97.4%), all p < 0.001. Twenty-three significant disproportionality signals were identified. The most clinically notable were a coagulopathic cluster - blood fibrinogen decreased (ROR 73.742, 95% CI 42.954-126.598; n = 16), lactic acidosis (ROR 57.803; n = 11), and hypertransaminasaemia (ROR 58.417; n = 10) - and pancreatitis (ROR 20.338; n = 8), not prominently described in the prescribing information. Indication-based off-label use accounted for 86.7% of cases (n = 137), predominantly for pulmonary Mycobacterium abscessus infection (17.7%). Quarterly reporting showed a significant upward trend (slope = 0.41 reports/quarter, R² = 0.256, p = 0.010). Eravacycline signals were observed for a lower reporting proportion of serious adverse outcomes compared with three active comparators. A distinctive coagulopathic and hepatic signal profile was identified, with pancreatitis as a potentially novel signal warranting prospective investigation. Off-label use, particularly for pulmonary Mycobacterium abscessus infection, predominates in real-world practice. These findings are hypothesis-generating and require validation in prospective, controlled studies.
Indexed as
Identifiers
42618637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.